COMMITMENTS AND CONTINGENCIES - Narrative (Details)		3 Months Ended		9 Months Ended		12 Months Ended
COMMITMENTS AND CONTINGENCIES - Narrative (Details)	Jun. 17, 2021 USD ($)	Sep. 30, 2022 USD ($) license_agreement	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) license_agreement	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Number of license agreements \| license_agreement		4		4
Payment of milestone license in intangibles and accrued expenses				$ 0	$ 1,000,000
Data Foundry Cloud Subscription
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Purchase commitment amount	$ 9,300,000
Purchase commitment period	3 years
Purchase liability		$ 2,983,000		2,983,000
Data Foundry Cloud Subscription \| Prepaid Expenses
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Purchase liability		2,321,000		2,321,000
Invention Science Fund I, LLC
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Royalty and maintenance expense		250,000	$ 250,000	750,000	750,000
Red 5 Group, LLC
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Royalty and maintenance expense		63,000	$ 63,000	188,000	$ 188,000
Red 5 Group, LLC \| License Agreement Terms
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Maximum payment, milestone achievement		400,000		$ 400,000
BeHealth Solutions, LLC \| License Agreement Terms
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Payment of milestone license in intangibles and accrued expenses						$ 1,000,000	$ 750,000
Useful life of capitalized milestone payments				5 years
Maximum payment, milestone achievement		26,000,000		$ 26,000,000
Waypoint Health Innovations, LLC \| License Agreement Terms
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Upfront payment				1,350,000
Upfront annual payment				250,000
Upfront payment liability		1,011,000		1,011,000
Maximum payment, milestone achievement		$ 2,500,000		$ 2,500,000
Amortization period				5 years
Proceeds from royalties				$ 0

Pear Therapeutics, Inc. 10-Q